Incidence of ESR1 mutations and best practices for testing

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses how ESR1 mutations (ESR1m) are commonly observed in HR+ breast cancer, particularly after prolonged endocrine therapy, and emphasizes the importance of molecular testing for ESR1m mutations at both the initial diagnosis of metastatic breast cancer (MBC) and at each subsequent progression using liquid biopsy assays.

EP: 1.Overview of Phase 3 EMERALD Study of Elacestrant for ER+, HER2–- MBC

Now Viewing

EP: 2.Incidence of ESR1 mutations and best practices for testing

1. How common are ESR1m in breast cancer? What is your approach toward molecular testing at initial diagnosis of MBC and each subsequent progression?

• Testing for ESR1m at each progression
• Assay (liquid)

Recent Videos